Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Articles

JAK2V617F-bearing vascular niche enhances malignant hematopoietic regeneration following radiation injury

Department of Medicine, Stony Brook School of Medicine, NY, USA
Biopharmaceutical R&D Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China
Office of the Sr. Vice President, Health Sciences, Stony Brook School of Medicine, NY, USA
Department of Medicine, Stony Brook School of Medicine, NY, USA;Northport VA Medical Center, Northport, NY, USA
Vol. 103 No. 7 (2018): July, 2018 https://doi.org/10.3324/haematol.2017.185736

Abstract

Myeloproliferative neoplasms are clonal stem cell disorders characterized by hematopoietic stem/progenitor cell expansion. The acquired kinase mutation JAK2V617F plays a central role in these disorders. Abnormalities of the marrow microenvironment are beginning to be recognized as an important factor in the development of myeloproliferative neoplasms. Endothelial cells are an essential component of the hematopoietic vascular niche. Endothelial cells carrying the JAK2V617F mutation can be detected in patients with myeloproliferative neoplasms, suggesting that the mutant vascular niche is involved in the pathogenesis of these disorders. Here, using a transgenic mouse expressing JAK2V617F specifically in all hematopoietic cells (including hematopoietic stem/progenitor cells) and endothelial cells, we show that the JAK2V617F-mutant hematopoietic stem/progenitor cells are relatively protected by the JAK2V617F-bearing vascular niche from an otherwise lethal dose of irradiation during conditioning for stem cell transplantation. Gene expression analysis revealed that chemokine (C-X-C motif) ligand 12, epidermal growth factor, and pleiotrophin are up-regulated in irradiated JAK2V617F-bearing endothelial cells compared to wild-type cells. Our findings suggest that the mutant vascular niche may contribute to the high incidence of disease relapse in patients with myeloproliferative neoplasms following allogeneic stem cell transplantation, the only curative treatment for these disorders.

Introduction

The chronic Philadelphia chromosome (Ph1) negative myeloproliferative neoplasms (MPNs) are clonal stem cell disorders characterized by hematopoietic stem/progenitor cell (HSPC) expansion and overproduction of mature blood cells. The acquired kinase mutation JAK2V617F plays a central role in MPNs. However, the mechanisms responsible for the malignant HSPC expansion in MPNs are not fully understood, limiting the effectiveness of current treatment. Although the etiology of dysregulated hematopoiesis has been mainly attributed to the molecular alterations within the HSPC compartment, abnormalities of the marrow microenvironment are beginning to be recognized as an important factor in the development of MPNs.51 The diseased niche could impair normal hematopoiesis and favor the competing malignant stem cells, which could contribute to the poor donor engraftment and high incidence of disease relapse following allogeneic stem cell transplantation (SCT), the only curative treatment for patients with MPNs.862

Endothelial cells (ECs) are an essential component of the hematopoietic niche and most HSPCs reside close to a marrow sinusoid (the “perivascular niche”).9 MPNs are characterized by increased marrow angiogenesis compared to normal marrow.1210 Although the existence and cell of origin of endothelial progenitors is still a subject of debate, JAK2V617F mutation can be detected in endothelial progenitors derived from the hematopoietic lineage (the so-called endothelial cell colony-forming units; CFU-ECs or Hill) and, in some reports, in the true endothelial colony-forming cells (ECFC) based on in vitro assays.1713 JAK2V617F mutation is also present in isolated liver or spleen ECs from patients with MPNs.1815 Previously, we and others have shown that JAK2V617F-bearing ECs are critical in the development of the bleeding abnormalities in a murine model of JAK2V617F-positive MPNs in which JAK2V617F is expressed in all hematopoietic cells and endothelial cells.19 In addition, we have reported that the JAK2V617F-bearing vascular niche promotes the expansion of the JAK2V617F HSPCs in preference to JAK2WT HSPCs.2120 All of these observations suggest that ECs are involved in the pathogenesis of MPNs.

In the present study, using the hematopoietic and endothelial specific Tie2-Cre system and different marrow transplantation models, we demonstrate that JAK2V617F-mutant HSPCs are relatively protected by the JAK2V617F-bearing vascular niche from the otherwise lethal irradiation administered during conditioning for marrow transplantation. Taken together, our studies indicate that the mutant vascular niche could contribute to the poor donor cell engraftment and the high incidence of disease relapse well known to occur in patients with MPNs after allogeneic SCT. Therefore, targeting the altered hematopoietic vascular niche could provide more effective therapies for patients with MPNs.

Methods

Experimental mice

JAK2V617F Flip-Flop (FF1) mice22 were provided by Radek Skoda (University Hospital, Basal, Switzerland) and Tie2-Cre mice23 by Mark Ginsberg (University of California, San Diego, USA). The FF1 mice were crossed with Tie2-Cre mice to express JAK2V617F specifically in hematopoietic cells and ECs (Tie2/FF1 mice). All mice used were crossed onto a C57BL/6 background and were bred in a pathogen-free mouse facility at Stony Brook University. CD45.1 congenic mice (SJL) were purchased from Taconic Inc. (Albany, NY, USA). Animal experiments were performed in accordance with the guidelines provided by the Institutional Animal Care and Use Committee.

Stem cell transplantation assays

The effects of the JAK2V617F-bearing vascular niche on MPN hematopoiesis were studied in vivo using marrow transplantation assays. First, we transplanted wild-type (WT) CD45.1 marrow cells into lethally irradiated (950cGy)2524 8-14-week old Tie2/FF1 mice or WT controls (CD45.2). Peripheral blood was obtained every four weeks after transplantation, and CD45.1 donor chimerism and complete blood counts were measured.

To study the effects of HSPC JAK2V617F mutation on HSPC radioprotection, we generated a chimeric murine model with JAK2V617F-mutant HSPCs and WT vascular niche by transplanting JAK2V617F marrow cells (CD45.2) into lethally irradiated (950cGy) WT recipients (CD45.1). The transplantation of CD45.2 WT marrow cells into CD45.1 WT recipients served as a control. Following hematopoietic recovery and full donor cell engraftment, each set of mice were irradiated with 300cGy to create a radiation injury. Two hours later, marrow Lineageneg (Lin-) HSPCs were isolated using Lineage Cell Depletion Kit (Miltenyi Biotec, San Diego, CA, USA) for evaluation of cellular apoptosis and cell cycle status. For competitive marrow transplantation experiments, 5×10 post-irradiated marrow cells (CD45.2) were injected intravenously together with 1×10 competitor CD45.1 WT marrow cells into lethally irradiated (950 cGy) CD45.1 recipients. Peripheral blood was obtained every four weeks after transplantation, and CD45.2 chimerism was measured.

To study the effects of EC JAK2V617F mutation on HSPC radio-protection, we generated a chimeric murine model with WT HSPCs and JAK2V617F-bearing vascular niche by transplanting WT marrow cells (CD45.1) into lethally irradiated (950cGy) Tie2/FF1 recipients (CD45.2). The transplantation of CD45.1 WT marrow cells into CD45.2 WT recipients served as a control. Following hematopoietic recovery and full donor cell engraftment, each set of mice were irradiated with 300cGy to create a radiation injury. Two hours later, marrow Lineageneg (Lin-) HSPCs were isolated for evaluation of cellular apoptosis.

Additional details of the methods used can be found in the Online Supplementary Methods.

Results

Expression of JAK2V617F in Tie2+ cells protects marrow HSPCs from lethal irradiation

Mice expressing Cre under the control of the Tie2 promoter (Tie2-Cre) were crossed with JAK2V617F Flip-Flop (FF1) mice to generate mice bearing human JAK2V617F expression specifically in endothelial and hematopoietic cells (Tie2/FF1). The Tie2/FF1 mice develop an MPN-like phenotype with neutrophilia, thrombocytosis, significant splenomegaly, and greatly increased marrow vascular density, megakaryopoiesis, and numbers of HSPCs.2019

To investigate the effects of the JAK2V617F-bearing vascular niche on MPN hematopoiesis in vivo, WT CD45.1 marrow cells were transplanted directly into lethally irradiated (950cGy) Tie2/FF1 mice or age-matched littermate control mice (CD45.2) (n=12 in each group) (Figure 1A). During a 3-month follow up, while all WT control recipients displayed full donor engraftment, 7 of 12 (approx. 60%) Tie2/FF1 recipient mice displayed recovery of JAK2V617F-mutant hematopoiesis (mixed donor/recipient chimerism) ten weeks after transplantation (Figure 1B).

Figure 1.JAK2V617F hematopoietic stem/progenitor cells (HSPCs) in the Tie2/FF1 mice are protected from lethal irradiation. (A) Scheme of direct marrow transplantation. (B) Peripheral blood CD45.1 chimerism following transplantation of wild-type (WT) CD45.1 marrow cells into lethally irradiated Tie2/FF1 mice or WT control mice (CD45.2) (n=12 in each group). (C) During more than eight months of follow up, Tie2/FF1 recipients with mixed chimerism developed both neutrophilia and thrombocytosis. (D) Spleens collected eight months following transplantation did not display significant weight differences between Tie2/FF1 recipients with full donor chimerism and WT recipients. In contrast, Tie2/FF1 recipients with mixed chimerism developed moderate splenomegaly compared to WT recipients (spleen weight 196 mg vs. 80 mg; P=0.010). (E) The frequency of normal marrow donor-derived E-SLAM (CD45.1) cells in the Tie2/FF1 recipients was unchanged from WT recipient mice. In contrast, JAK2V617F-mutant recipient-derived E-SLAM (CD45.2) cells were significantly expanded in Tie2/FF1 recipients with mixed chimerism. (F) Schematic diagram of irradiation and analysis of Tie2/FF1 and WT control mice. (G) Lin− HSPC cell apoptosis in Tie2-cre control or Tie2/FF1 mice after 300cGy irradiation (n=2 in each group). *P<0.05.

We followed some of the Tie2/FF1 and WT control recipients (n=7 in each group) for more than eight months. In contrast to the Tie2/FF1 recipients with full donor engraftment, the mixed chimeric mice developed neutrophilia, thrombocytosis, and splenomegaly (Figure 1C and D), similar to what has been observed in the primary Tie2/FF1 mice.2619 Flow cytometry analysis revealed that JAK2V617F-mutant CD45.2EPCRCD48CD150 (E-SLAM) cells, which is a highly purified long-term repopulating HSPC population in normal and in MPN marrow,2827 are significantly expanded in the mixed chimeric mice compared to Tie2/FF1 recipients with full donor engraftment or WT recipients (Figure 1E).

In virtually all our transplantation experiments performed over the past four years, we have used 950cGy radiation24 and have seen virtually 100% donor engraftment in every recipient. In contrast, 7 of 12 mice in our Tie2/FF1 recipients of normal marrow demonstrated mixed chimerism with an average of 23% recipient cells in peripheral blood at fourteen weeks following 950cGy irradiation and marrow transplantation, and developed an MPN phenotype resembling the primary Tie2/FF1 mice during more than eight months of follow up. These findings suggest that the JAK2V617F-mutant HSPCs in Tie2/FF1 mice are relatively protected from the otherwise lethal irradiation administered during conditioning for marrow transplantation. To confirm this hypothesis, we irradiated primary Tie2/FF1 mice or Tie2-cre control mice with 300cGy, and two hours later their marrow Lin-HSPCs were isolated for evaluation of cellular apoptosis (Figure 1F). We found that the JAK2V617F HSPCs in the mutant vascular niche (i.e. Tie2/FF1 mice) had significantly less cellular apoptosis compared to JAK2V617F HSPCs in WT vascular niche (i.e. control mice) (12.1% vs. 25.8%; P=0.043) (Figure 1G). Therefore, the JAK2V617F-mutant HSPCs in Tie2/FF1 mice are relatively protected from lethal irradiation, which could be responsible for the reported high incidence of disease relapse in patients undergoing allogeneic SCT for MPNs.762

The JAK2V617F-mutant HSPC is more sensitive to radiation-induced apoptosis than JAK2WT HSPC

Tie2-Cre mice express Cre recombinase in both ECs and hematopoietic cells. To investigate whether the radioprotection phenotype noted in the prior experiments is due to the JAK2V617F mutation in Tie2/FF1 HSPCs, we generated a chimeric murine model with JAK2V617F-mutant HSPCs and a WT vascular niche by transplanting Tie2/FF1 marrow cells into WT recipients. The transplantation of WT marrow cells into WT recipients served as a control. Following hematopoietic recovery and full donor cell engraftment, each set of mice were again irradiated with 300cGy to create a radiation injury, and two hours later, marrow Lineageneg (Lin-) HSPCs were isolated for evaluation of cellular apoptosis and cell cycle status. In our previous study, recipient mice of Tie2/FF1 marrow developed a MPN phenotype by eight weeks post transplantation with significant thrombocytosis and neutrophilia.19 Therefore, we irradiated the mice at six weeks post transplant in this study before the development of any clinical phenotype (data not shown) (Figure 2A). We found that cell apoptosis was significantly increased in the JAK2V617F-mutant HSPCs compared to JAK2WT HSPCs (47.3% vs. 20.3%; P=0.005) (Figure 2B). This result is consistent with the observation that unirradiated JAK2V617F Lin HSPCs proliferate to a greater extent than JAK2WT Lin HSPCs in serum-free medium in vitro (5.8-fold; P=0.000006) (Figure 2C), and therefore are predictably more sensitive to radiation-induced apoptosis. There was no significant difference in cell cycle status between the JAK2V617F HSPCs and JAK2WT HSPCs after irradiation. These data suggest that, in the WT vascular niche, the JAK2V617F-mutant HSPC is more (not less) sensitive to radiation-induced apoptosis than are JAK2WT HSPCs.

Figure 2.The JAK2V617F-mutant hematopoietic stem/progenitor cell (HSPC) is more sensitive to radiation-induced apoptosis than JAK2WT HSPC. (A) Outline of experiment design to generate a chimeric murine model with JAK2V617F-mutant HSPCs and wild-type (WT) vascular niche. (B) After 300cGy irradiation, cell apoptosis (Annexin V+7AAD−) was significantly increased in JAK2V617F Lin− HSPCs (black bar) compared to JAK2WT Lin− HSPCs (gray bar). (C) Unirradiated JAK2V617F (black) Lin− HSPCs proliferated to a greater extent than JAK2WT (gray) Lin− HSPCs in vitro. (D) Peripheral blood donor chimerism following a competitive repopulation assay in which 5×105 post-irradiated JAK2WT or JAK2V617F marrow cells (CD45.2) were injected together with 1×105 competitor CD45.1 WT marrow cells into lethally irradiated CD45.1 WT recipients (n=4 in each group). *P<0.05.

To further test the effect of irradiation on HSPC function in the WT vascular niche, we performed a competitive repopulation assay in which 5×10 post-irradiated marrow cells (CD45.2 JAK2WT or CD45.2 JAK2V617F) were injected intravenously together with 1×10 competitor CD45.1 WT marrow cells into lethally irradiated (950 cGy) CD45.1 recipients (Figure 2A). Since the presence of JAK2V617F mutation in HSPCs may affect the cell’s long-term proliferation, we focused on donor cell chimerism in the early phase of engraftment. During an 8-week post-transplant follow up, there was no difference in CD45.2 donor chimerism between the recipients of post-irradiated JAK2V617F marrow cells and recipients of post-irradiated JAK2WT marrow cells, suggesting that the engraftment potential of post-irradiated JAK2V617F HSPCs (or at least the short-term HSPCs) do not differ from JAK2WT HSPCs (Figure 2D).

JAK2V617F-bearing ECs protect HSPCs from lethal irradiation

We next studied the effects of an EC JAK2V617F mutation on hematopoietic radioprotection. Lin- marrow HSPCs were isolated from WT or Tie2/FF1 mice and cultured on primary EC feeder layers derived from WT or Tie2/FF1 (JAK2V617F) murine lungs. The Lin- HSPC-EC co-cultures were irradiated with 300cGy ex vivo and cell number was counted within 24 hours of irradiation. We observed higher total cell numbers (1.6-fold; P=0.026) and hematopoietic progenitors (1.3-fold; P=0.010) from JAK2V617F HSPCs cultured on JAK2V617F-bearing ECs compared to their being cultured on JAK2WT ECs, suggesting that the JAK2V617F-bearing vascular niche contributes directly to JAK2V617F-mutant HSPC radioprotection (Figure 3A and B). No significant difference was observed in cell numbers or hematopoietic progenitors between JAK2WT HSPCs cultured on JAK2V617F-bearing ECs and their being cultured on JAK2WT ECs in vitro after irradiation.

Figure 3.The JAK2V617F-bearing endothelial cells (ECs) protect JAK2V617F hematopoietic stem/progenitor cells (HSPCs) from lethal irradiation. (A and B) After 300cGy irradiation, there were higher total cell numbers (1.6-fold; P=0.026) (A) and hematopoietic progenitors (1.3-fold; P=0.010) (B) from JAK2V617F Lin− HSPCs cultured on JAK2V617F-bearing ECs compared to their being cultured on JAK2WT ECs. Cell numbers were shown as the relative ratio compared to JAK2WT Lin− HSPCs cultured on JAK2WT ECs under the same conditions. Data are from 3 independent experiments. (C) Outline of experiment design to generate a chimeric murine model with JAK2WT HSPCs and mutant vascular niche which is then subjected to sublethal irradiation. (D) CD45.1 WT Lin− HSPC cell apoptosis in WT or JAK2V617F-mutant vascular niche after 300cGy irradiation (n=4 in each group).

To further investigate the effects of JAK2V617F-bearing vascular niche on the response of HSPCs to radiation injury in vivo, we generated a chimeric murine model with WT HSPCs and JAK2V617F-bearing vascular niche by transplanting WT marrow cells (CD45.1) into lethally irradiated (950cGy) Tie2/FF1 recipients (CD45.2). The transplantation of CD45.1 WT marrow cells into CD45.2 WT recipients served as a control (Figure 3C). Based on our observation that Tie2/FF1 recipients did not develop any significant recovery of the JAK2V617F-mutant hematopoiesis until ten weeks after transplantation (Figure 1B), each set of chimeric mice were irradiated with 300cGy at 6-10 weeks following transplantation to create a radiation injury. Two hours later, marrow Lin HSPCs were isolated for evaluation of cellular apoptosis. We found that the WT Lin- HSPC cell apoptosis was decreased in the JAK2V617F-mutant vascular niche compared to WT vascular niche (12.7% vs. 19.7%; P=0.034) (Figure 3D). Taken together, these data suggest that the JAK2V617F-bearing vascular niche contributes directly to HSPC radioprotection.

In contrast to our observations in vivo, where JAK2V617F-mutant HSPCs had increased apoptosis compared to JAK2WT HSPCs in the WT vascular niche (Figure 2A and B), cell numbers or progenitor numbers from the JAK2V617F HSPCs and JAK2WT HSPCs were similar when cultured on JAK2WT ECs (Figure 3A and B). Similarly, while the JAK2V617F-bearing vascular niche is protective for WT HSPCs in vivo (Figure 3C and D), JAK2V617F EC did not significantly protect WT HSPC in vitro (Figure 3A and B). These results are likely due to the different cell-cell interactions and niche factors between the in vitro culture condition and in vivo microenvironment.

The JAK2V617F mutation alters vascular niche function to contribute to HSPC radioprotection

Next, we investigated how the JAK2V617F mutation alters EC function in the vascular niche to protect HSPCs from radiation injury. In our previous studies, we found that JAK2V617F-bearing ECs proliferate to a greater extent than JAK2WT ECs and display significantly increased angiogenesis in vitro compared to JAK2WT ECs. In addition, the tubular structures formed by the JAK2V617F-bearing ECs in vitro were more stable than those from JAK2WT ECs.21 In this study, we found that JAK2V617F lung ECs displayed less cell apoptosis in vitro after 300cGy irradiation compared to JAK2WT ECs (7.7% vs. 19.5%; P=0.026) (Figure 4A). It has long been known that hematopoietic recovery following lethal irradiation requires an intact vasculature.3429 Therefore, the increased cell proliferation and/or decreased apoptosis could expand the vascular niche in JAK2V617F-bearing mice, which in turn contributes to the hematopoietic radioprotection we have observed in the Tie2/FF1 recipient mice.

Figure 4.The JAK2V617F mutation alters vascular niche function to contribute to hematopoietic stem/progenitor cell (HSPC) radioprotection. (A) After 300cGy irradiation, cell apoptosis was higher in the JAK2WT endothelial cells (ECs) than JAK2V617F ECs. Data are from 1 of 3 independent experiments that gave similar results. (B and C) The expression levels of CXCL12, EGF and PTN in unirradiated (B) and irradiated (C) JAK2V617F-bearing ECs compared to irradiated JAK2WT ECs. Gene expression is shown as the relative fold-change compared with the JAK2WT EC expression which was set as 1. (D) Representative histogram plots and flow cytometry quantitative analysis of phosphorylated EGFR expression in irradiated JAK2WT HSPCs [from wild-type (WT) control mice] and JAK2V617F HSPCs (from Tie2/FF1 mice) (n=2 in each group).

CXCL12 is an essential niche factor important for both HSPC maintenance and HSPC survival after radiation injury.3835 Epidermal growth factor (EGF) and pleiotrophin (PTN), two other factors secreted by the vascular niche, have been shown to play important roles in the regulation of HSPC regeneration following radiation injury.4139 Recently, we demonstrated that the expression level of CXCL12 was up-regulated in JAK2V617F-bearing marrow ECs compared to wild-type ECs, which could mediate the clonal expansion of JAK2V617F HSPCs, via the up-regulated CXCL12 receptor CXCR4, over JAK2WT HSPCs.20 To understand the EC signals responsible for HSPC radioprotection in the Tie2/FF1 recipient mice, we measured the expression levels of CXCL12, EGF, and PTN in both non-irradiated and irradiated JAK2WT and JAK2V617F lung ECs. qPCR analysis confirmed that there was upregulation of CXCL12 (2.5-fold; P=0.0001), EGF (4.0-fold; P=0.011) and PTN (11.4-fold; P=0.00001) in irradiated JAK2V617F-bearing ECs compared to irradiated JAK2WT ECs (Figure 4B and C). Furthermore, quantitative flow cytometry analysis showed that the proportion of marrow CD150CD48 HSPCs expressing phosphorylated EGFR was increased in irradiated JAK2V617F HSPCs (from Tie2/FF1 mice) as compared to irradiated JAK2WT HSPCs (from control mice) (2.7-fold; P=0.042), suggesting that EGFR signaling activity was up-regulated in irradiated JAK2V617F HSPCs (Figure 4D). These results suggest that the JAK2V617F-bearing vascular niche contributes directly to HSPC radioprotection, possibly by its elaboration of soluble niche factors.

Discussion

Vascular ECs are a major component of the HSPC niche (the “vascular niche”) and provide many key factors that are required for HSPC maintenance.9 Patients with MPNs are characterized by increased marrow angiogenesis compared to normal marrow.1210 ECs carrying the JAK2V617F mutation can be detected in patients with MPNs, suggesting that ECs are involved in the pathogenesis of MPNs.1815 Here, by using the hematopoietic and endothelial specific Tie2-Cre system and different marrow transplantation models, we have been able to highlight the importance of JAK2V617F-bearing ECs in MPN disease relapse, which is seen in up to 40% of patients (especially after reduced intensity conditioning) following allogeneic SCT, the only curative treatment for MPNs.444286

It has long been known that hematopoietic recovery following lethal irradiation requires an intact vasculature.3429 Following radiation injury, co-culture of irradiated HSPCs with ECs can rescue HSPCs with multilineage reconstituting capacity.4645 Our previous study has demonstrated that JAK2V617F-bearing ECs proliferate to a greater extent than JAK2WT ECs in vitro.21 In this study, we show that the JAK2V617F-bearing ECs display less cell apoptosis in vitro after irradiation compared to JAK2WT ECs. In addition, the JAK2V617F-mutant Lin HSPCs produce more cells and hematopoietic colonies after irradiation when cultured on JAK2V617F-bearing ECs compared to their being cultured on JAK2WT ECs. Moreover, the expression levels of CXCL12, EGF, and PTN, which are important niche factors involved in HSPC maintenance and/or HSPC regeneration following radiation injury, were up-regulated in irradiated JAK2V617F-bearing ECs compared to JAK2WT ECs (Figures 3 and 4). These results suggest that the JAK2V617F-bearing vascular niche contribute directly to HSPC radioprotection. Consistent with these findings, 7 of 12 mice in our Tie2/FF1 recipients of normal marrow demonstrated mixed chimerism of an average 77% donor in peripheral blood cells at fourteen weeks following transplantation (Figure 1B). Previously we reported that the JAK2V617F-bearing vascular niche promotes the expansion of the JAK2V617F HSPCs in preference to JAK2WT HSPCs and the development of marrow fibrosis.20 Since graft failure or poor graft function in MPN patients after SCT is most likely due to marrow fibrosis,44 our work has demonstrated that the mutant vascular niche can contribute to the poor donor cell engraftment and the high incidence of disease relapse, the two major causes of treatment-related morbidity and mortality associated with allogeneic SCT in patients with MPNs.44762

The Tie2-Cre mice express Cre recombinase in both ECs and hematopoietic cells. Although an EC-specific Cre (e.g. VEcadherin-Cre) would allow us to distinguish the specific role of ECs in HSPC radioprotection, we chose to use Tie2-Cre as it mimics the human MPNs in which both the HSPCs and ECs harbor the JAK2V617F mutation. In order to determine whether the radioprotection phenotype we have observed in the Tie2/FF1 mice is also due to the JAK2V617F mutation in HSPCs, we generated a chimeric murine model with JAK2V617F-mutant HSPCs and a WT vascular niche using marrow transplantation. We found that, in the WT vascular niche, the JAK2V617F-mutant Lin- HSPC is more (not less) sensitive to radiation-induced apoptosis than JAK2WT HSPCs. Although there have been reports that EC infusion could augment hematopoietic recovery following myeloablative injury, transplanted ECs exert their pro-regenerative effect transiently, and there is no evidence that donor marrow ECs could engraft and achieve long-term reconstitution in the recipient marrow vascular niche.473231 Therefore, analysis six weeks post transplantation (Figure 2A and B) is unlikely to be affected by “carry-over” ECs from the Tie2/FF1 donor at the time of transplantation. In addition, the engraftment potential of irradiated JAK2V617F-mutant HSPCs does not differ from irradiated JAK2WT HSPCs (Figure 2). The results of these studies suggest that the radioprotection phenotype we have observed in the Tie2/FF1 recipients is unlikely to be due solely to the presence of the JAK2V617F mutation in HSPCs. In contrast, in another chimeric murine model with WT HSPCs and JAK2V617F-bearing vascular niche, WT Lin HSPC is less sensitive to radiation-induced apoptosis in the JAK2V617F-mutant vascular niche compared to WT vascular niche (Figure 3). These results suggest that JAK2V617F-bearing vascular niche contributes directly to HSPC radioprotection.

We could not exclude the possibility that altered interactions between the JAK2V617F HSPCs and JAK2V617F ECs contribute to HSPC radioprotection in the Tie2/FF1 mice. Indeed, no significant difference was observed in cell numbers or hematopoietic progenitors between JAK2WT HSPCs cultured on JAK2V617F-bearing ECs compared to their being cultured on JAK2WT ECs after irradiation (Figure 3A and B). This observation suggests that the JAK2V617F-bearing vascular niche by itself may not be sufficient to account for the radioprotection phenotype. Rather, it is most likely that specific cell-cell interactions involving the stem cells and niche ECs are required to provide the radioprotection of JAK2V617F HSPCs when present in a JAK2V617F vascular niche, as exemplified by the up-regulated EGF-EGFR signaling reported in this study (Figure 4). Systemic analysis of HSPC and EC proteins using either quantitative proteomics or antibody-based arrays, along with specific knock-out mouse models would be required to further investigate the interactions between HSPCs and ECs in JAK2V617F-bearing MPNs in vitro and in vivo.

Although the JAK2V617F mutation has only been reported in liver and spleen ECs from patients with MPNs,1815 it is very probably also present in their marrow ECs, considering that liver, spleen, and marrow are all hematopoietic organs during embryonic development and/or throughout adulthood. In most MPN patients, the stem cell compartment in MPN is heterogeneous with the presence of both JAK2 wild-type clones and the JAK2V617F mutant clones. We hypothesize that the vascular niche in MPN patients is also heterogeneous with the co-existence of both normal and mutant ECs. Since the JAK2V617F mutation is present in all HSPCs and ECs from birth in the Tie2/FF1 mice, our murine model may not present the same acquired clonality and heterogeneous vascular niche features that characterize patients with MPNs. Nonetheless, our study has demonstrated that the JAK2V617F-bearing vascular niche can protect the JAK2V617F HSPCs from the otherwise lethal irradiation administered during conditioning for marrow transplantation, which provides a mechanism for the high incidence of disease relapse in MPN patients after allogeneic SCT. The optimal conditioning regimen for MPN patients undergoing SCT has still not been determined.4844 As most current conditioning regimens for SCT are not restricted to only radiation, further investigation using murine models with different quantities of mutant ECs versus WT ECs will be required to fully understand the effects of the JAK2V617F-bearing vascular niche on mutant HSPC expansion and HSPC resistance to lethal irradiation and the cytotoxic chemotherapies commonly used in SCT for patients with MPNs.

Acknowledgments

The authors thank Todd Rueb and Rebecca Connor (Flow Cytometry Core Facility, Stony Brook University, NY, USA) for their assistance with the flow cytometry experiments. We would also like to thank Dr. Yupo Ma (Stony Brook University, NY, USA) for his continuous support throughout this work. YZ is supported by the State Scholarship Fund from Chinese Scholarship Council.

Footnotes

  • ↵* CHSL and YZ contributed equally to this work.
  • Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/103/7/1160
  • FundingThis research was supported by the Veterans Affairs award IK2BX001559 (HZ) and National Heart, Lung, and Blood Institute grant R01 HL134970 (HZ).
  • Received December 1, 2017.
  • Accepted March 14, 2018.

References

  1. Walkley CR, Olsen GH, Dworkin S. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell. 2007; 129(6):1097-1110. PubMedhttps://doi.org/10.1016/j.cell.2007.05.014Google Scholar
  2. Schepers K, Pietras EM, Reynaud D. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell. 2013; 13(3):285-299. PubMedhttps://doi.org/10.1016/j.stem.2013.06.009Google Scholar
  3. Arranz L, Sanchez-Aguilera A, Martin-Perez D. Neuropathy of haematopoi-etic stem cell niche is essential for myeloproliferative neoplasms. Nature. 2014; 512(7512):78-81. PubMedhttps://doi.org/10.1038/nature13383Google Scholar
  4. Mager LF, Riether C, Schurch CM. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. J Clin Invest. 2015; 125(7):2579-2591. PubMedhttps://doi.org/10.1172/JCI77347Google Scholar
  5. Walkley CR, Shea JM, Sims NA, Purton LE, Orkin SH. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell. 2007; 129(6):1081-1095. PubMedhttps://doi.org/10.1016/j.cell.2007.03.055Google Scholar
  6. Kroger N, Holler E, Kobbe G. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multi-center study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009; 114(26):5264-5270. PubMedhttps://doi.org/10.1182/blood-2009-07-234880Google Scholar
  7. Rondelli D, Goldberg JD, Isola L. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014; 124(7):1183-1191. PubMedhttps://doi.org/10.1182/blood-2014-04-572545Google Scholar
  8. Patriarca F, Bacigalupo A, Sperotto A. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica. 2008; 93(10):1514-1522. PubMedhttps://doi.org/10.3324/haematol.12828Google Scholar
  9. Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014; 505(7483):327-334. PubMedhttps://doi.org/10.1038/nature12984Google Scholar
  10. Medinger M, Skoda R, Gratwohl A. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br J Haematol. 2009; 146(2):150-157. PubMedhttps://doi.org/10.1111/j.1365-2141.2009.07726.xGoogle Scholar
  11. Boveri E, Passamonti F, Rumi E. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. Br J Haematol. 2008; 140(2):162-168. PubMedGoogle Scholar
  12. Gianelli U, Vener C, Raviele PR. VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders. Am J Clin Pathol. 2007; 128(6):966-973. PubMedhttps://doi.org/10.1309/FP0N3LC8MBJUFFA6Google Scholar
  13. Yoder MC, Mead LE, Prater D. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007; 109(5):1801-1809. PubMedhttps://doi.org/10.1182/blood-2006-08-043471Google Scholar
  14. Teofili L, Martini M, Iachininoto MG. Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood. 2011; 117(9):2700-2707. PubMedhttps://doi.org/10.1182/blood-2010-07-297598Google Scholar
  15. Rosti V, Villani L, Riboni R. Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood. 2013; 121(2):360-368. PubMedhttps://doi.org/10.1182/blood-2012-01-404889Google Scholar
  16. Sozer S, Ishii T, Fiel MI. Human CD34+ cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivo. Blood Cells Mol Dis. 2009; 43(3):304-312. PubMedhttps://doi.org/10.1016/j.bcmd.2009.08.005Google Scholar
  17. Piaggio G, Rosti V, Corselli M. Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker. Blood. 2009; 114(14):3127-3130. PubMedhttps://doi.org/10.1182/blood-2008-12-190991Google Scholar
  18. Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009; 113(21):5246-5249. PubMedhttps://doi.org/10.1182/blood-2008-11-191544Google Scholar
  19. Etheridge SL, Roh ME, Cosgrove ME. JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms. Proc Natl Acad Sci USA. 2014; 111(6):2295-2300. PubMedhttps://doi.org/10.1073/pnas.1312148111Google Scholar
  20. Zhan H, Lin CHS, Segal Y, Kaushansky K. The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms. Leukemia. 2018; 32(2):462-469. Google Scholar
  21. Lin CH, Kaushansky K, Zhan H. JAK2V617F-mutant vascular niche contributes to JAK2V617F clonal expansion in myeloproliferative neoplasms. Blood Cells Mol Dis. 2016; 62:42-48. https://doi.org/10.1016/j.bcmd.2016.09.004Google Scholar
  22. Tiedt R, Hao-Shen H, Sobas MA. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008; 111(8):3931-3940. PubMedhttps://doi.org/10.1182/blood-2007-08-107748Google Scholar
  23. Constien R, Forde A, Liliensiek B. Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis. 2001; 30(1):36-44. PubMedhttps://doi.org/10.1002/gene.1030Google Scholar
  24. Duran-Struuck R, Dysko RC. Principles of bone marrow transplantation (BMT): providing optimal veterinary and husbandry care to irradiated mice in BMT studies. J Am Assoc Lab Anim Sci. 2009; 48(1):11-22. PubMedGoogle Scholar
  25. Grahn D, Hamilton KF. Genetic Variation in the Acute Lethal Response of Four Inbred Mouse Strains to Whole Body X-Irradiation. Genetics. 1957; 42(3):189-198. PubMedGoogle Scholar
  26. Sangkhae V, Etheridge SL, Kaushansky K, Hitchcock IS. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm. Blood. 2014; 124(26):3956-3963. PubMedhttps://doi.org/10.1182/blood-2014-07-587238Google Scholar
  27. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005; 121(7):1109-1121. PubMedhttps://doi.org/10.1016/j.cell.2005.05.026Google Scholar
  28. Kent DG, Copley MR, Benz C. Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential. Blood. 2009; 113(25):6342-6350. PubMedhttps://doi.org/10.1182/blood-2008-12-192054Google Scholar
  29. Hooper AT, Butler JM, Nolan DJ. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell. 2009; 4(3):263-274. PubMedhttps://doi.org/10.1016/j.stem.2009.01.006Google Scholar
  30. Doan PL, Russell JL, Himburg HA. Tie2(+) bone marrow endothelial cells regulate hematopoietic stem cell regeneration following radiation injury. Stem Cells. 2013; 31(2):327-337. PubMedGoogle Scholar
  31. Chute JP, Muramoto GG, Salter AB. Transplantation of vascular endothelial cells mediates the hematopoietic recovery and survival of lethally irradiated mice. Blood. 2007; 109(6):2365-2372. PubMedhttps://doi.org/10.1182/blood-2006-05-022640Google Scholar
  32. Salter AB, Meadows SK, Muramoto GG. Endothelial progenitor cell infusion induces hematopoietic stem cell reconstitution in vivo. Blood. 2009; 113(9):2104-2107. PubMedhttps://doi.org/10.1182/blood-2008-06-162941Google Scholar
  33. Li B, Bailey AS, Jiang S, Liu B, Goldman DC, Fleming WH. Endothelial cells mediate the regeneration of hematopoietic stem cells. Stem Cell Res. 2010; 4(1):17-24. PubMedhttps://doi.org/10.1016/j.scr.2009.08.001Google Scholar
  34. Himburg HA, Sasine J, Yan X, Kan J, Dressman H, Chute JP. A Molecular Profile of the Endothelial Cell Response to Ionizing Radiation. Radiat Res. 2016; 186:141-52. Google Scholar
  35. Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012; 481(7382):457-462. PubMedhttps://doi.org/10.1038/nature10783Google Scholar
  36. Ding L, Morrison SJ. Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature. 2013; 495(7440):231-235. PubMedhttps://doi.org/10.1038/nature11885Google Scholar
  37. Greenbaum A, Hsu YM, Day RB. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature. 2013; 495(7440):227-230. PubMedhttps://doi.org/10.1038/nature11926Google Scholar
  38. Foudi A, Jarrier P, Zhang Y. Reduced retention of radioprotective hematopoietic cells within the bone marrow microenvironment in CXCR4−/− chimeric mice. Blood. 2006; 107(6):2243-2251. PubMedhttps://doi.org/10.1182/blood-2005-02-0581Google Scholar
  39. Doan PL, Himburg HA, Helms K. Epidermal growth factor regulates hematopoietic regeneration after radiation injury. Nat Med. 2013; 19(3):295-304. PubMedhttps://doi.org/10.1038/nm.3070Google Scholar
  40. Himburg HA, Muramoto GG, Daher P. Pleiotrophin regulates the expansion and regeneration of hematopoietic stem cells. Nat Med. 2010; 16(4):475-482. PubMedhttps://doi.org/10.1038/nm.2119Google Scholar
  41. Himburg HA, Doan PL, Quarmyne M. Dickkopf-1 promotes hematopoietic regeneration via direct and niche-mediated mechanisms. Nat Med. 2017; 23(1):91-99. Google Scholar
  42. Guardiola P, Anderson JE, Bandini G. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood. 1999; 93(9):2831-2838. PubMedGoogle Scholar
  43. Ballen KK, Shrestha S, Sobocinski KA. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2010; 16(3):358-367. PubMedhttps://doi.org/10.1016/j.bbmt.2009.10.025Google Scholar
  44. Kroger N. Current Challenges in Stem Cell Transplantation in Myelofibrosis. Curr Hematol Malig Rep. 2015; 10(4):344-350. Google Scholar
  45. Chute JP, Clark W, Saini A, Wells M, Harlan D. Rescue of hematopoietic stem cells following high-dose radiation injury using ex vivo culture on endothelial monolayers. Mil Med. 2002; 167(2 Suppl):74-77. PubMedGoogle Scholar
  46. Chute JP, Fung J, Muramoto G, Erwin R. Ex vivo culture rescues hematopoietic stem cells with long-term repopulating capacity following harvest from lethally irradiated mice. Exp Hematol. 2004; 32(3):308-317. PubMedhttps://doi.org/10.1016/j.exphem.2003.12.002Google Scholar
  47. Poulos MG, Crowley MJ, Gutkin MC. Vascular Platform to Define Hematopoietic Stem Cell Factors and Enhance Regenerative Hematopoiesis. Stem Cell Reports. 2015; 5(5):881-894. https://doi.org/10.1016/j.stemcr.2015.08.018Google Scholar
  48. Spivak JL. Myeloproliferative Neoplasms. N Engl J Med. 2017; 376(22):2168-2181. Google Scholar

Article Information

Vol. 103 No. 7 (2018): July, 2018 : Articles
 
DOI
https://doi.org/10.3324/haematol.2017.185736
Pubmed
29567773
Pubmed Central
PMC6029534
 
Published
2018-07-01
Published By
Ferrata Storti Foundation, Pavia, Italy
Print ISSN
0390-6078
Online ISSN
1592-8721
 

Article Usage

Online Views
804
PDF Downloads
231

Statistics from Altmetric.com

No Data
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2024 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online